An increasing number of Left Ventricular Assisted Devices (LVADs) are implanted worldwide each year as a therapy for heart failure. However, complications arising from LVADs implantation can lead to serious consequences and potentially fatal outcomes for patients. Blood cells are subjected to non-physiological flow and iterative contacts with exogenous materials. Combination of these two factors promotes activation, adhesion and subsequent aggregation of platelets on the material surface, leading to thrombi formation and thromboembolic events. Lifelong treatments with antiplatelet and anticoagulant drugs are necessary to moderate these risks. However, while reducing the risk of prothrombotic complications, these treatments increase the risk of excessive bleeding.